Postexposure Treatment of Marburg Virus Infection
- 1 July 2010
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 16 (7), 1119-1122
- https://doi.org/10.3201/eid1607.100159
Abstract
Rhesus monkeys are protected from disease when a recombinant vesicular stomatitis virus–based vaccine is administered 20–30 min after infection with Marburg virus. We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals were protected when the vaccine was administered 48 h postinfection.Keywords
This publication has 12 references indexed in Scilit:
- Managing Potential Laboratory Exposure to Ebola Virus by Using a Patient Biocontainment Care Unit1Emerging Infectious Diseases, 2008
- Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman PrimatesJournal of Virology, 2008
- Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic FeverThe Journal of Infectious Diseases, 2007
- Effective Post-Exposure Treatment of Ebola InfectionPLoS Pathogens, 2007
- Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA InterferenceThe Journal of Infectious Diseases, 2006
- Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessmentThe Lancet, 2006
- VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in MiceAntimicrobial Agents and Chemotherapy, 2006
- Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino OligomersPLoS Pathogens, 2006
- Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and ArenavirusesJournal of Virology, 2004
- Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeysThe Lancet, 2003